OncoMatch/Clinical Trials/NCT03280511

Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients

Is NCT03280511 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PIPAC for peritoneum cancer.

Phase 2RecruitingMichael Bau MortensenNCT03280511Data as of May 2026

Treatment: PIPAC — In this study, patients will be offered two Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) treatments with oxaliplatin after primary resection and standard adjuvant chemotherapy (if indicated) for colon cancer. Furthermore, the study will explore, whether it is possible to find free intraperitoneal tumor cells (FITC) after resection and adjuvant chemotherapy for colon cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Colorectal Cancer

Disease stage

Required: Stage PT4NANYM0, PTANYNANYM1 (UICC 8th edition)

high-risk tumors defined as: perforated / pT4NanyM0 (UICC 8th edition) / pTanyNanyM1 with radically resected PM including ovarian metastases

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: cytoreductive surgery with hipec

Lab requirements

Blood counts

anc > 1.5 x 10^9/l and platelets > 100 x 10^9/l

Kidney function

gfr >= 50 ml/min (cockcroft-gault equation)

Liver function

bilirubin < 1.5 x unl

Cardiac function

nyha class <= 2

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify